Radius Health Announces Three Presentations on Elacestrant (RAD1901) and RAD140 at the 2017 American Association for Cancer Research Annual Meeting (AACR)

On March 31, 2017 Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, reported that it will present new preclinical data on elacestrant (RAD1901), an oral selective estrogen degrader, in ER-positive breast cancer and two posters regarding RAD140, an oral non-steroidal selective androgen receptor modulator, at the AACR (Free AACR Whitepaper) Annual Meeting 2017 on April 1-5, 2017 at the Walter E. Washington Convention Center in Washington D.C (Press release, Radius, MAR 31, 2017, View Source [SID1234518349]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details on the three poster presentations are as follows:

Abstract Title: Impact of oral selective estrogen receptor degrader elacestrant (RAD1901) in preclinical models of endocrine sensitive/resistant breast cancer (preclinical)
Abstract Number: 4160
Session Title: Novel Mechanisms 2
Session Date: April 4, 2017
Session Time: 1:00 — 5:00 PM

Abstract Title: RAD140, an orally available selective androgen receptor modulator, inhibits the growth of AR/ER positive breast cancer cell line- and patient-derived xenograft models
Abstract Number: 3608
Session Title: Endocrine Oncology Therapies
Session Date: April 4, 2017
Session Time: 8:00 AM — 12:00 PM

Abstract Title: RAD140, a selective androgen receptor modulator, has a differentiated mechanism of action in AR/ER positive breast cancers
Abstract Number: 3609
Session Title: Endocrine Oncology Therapies
Session Date: April 4, 2017
Session Time: 8:00 AM — 12:00 PM

Abstracts for each poster and additional information on the meeting can be found on the AACR (Free AACR Whitepaper) website: www.aacr.org/.